Regeneron announced that their bispecific odronextamab had the highest recorded complete response rate for follicular lymphoma, but the therapeutic antibody’s safety profile has thrown up several concerns.
Key opinion leaders share their thoughts on the prospect of effector cell redirection and cell engagers at Biologics UK: In-Person 2022.
Edited by Tia Byer |
07 June 2022
Search by Keyword
Filter by Subject Area
Filter by Content Type
We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.